Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear.
Gibson
C Michael
CM
Pride
Yuri B
YB
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D006801:Humans; D019028:Magnetic Resonance Imaging, Cine; D009203:Myocardial Infarction / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D009206:Myocardium / Q000473:pathology*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D057127:Single-Chain Antibodies / Q000627:therapeutic use*; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002317:Cardiovascular Agents; D057127:Single-Chain Antibodies; C402724:pexelizumab